Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPX-303 in advanced solid tumors
NCT06259552Phase 1Recruiting
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPX-303 in solid tumor, head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC) and 1 more (2 arms). Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Related Adverse Events at 3.5 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
SPX-303
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06259552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259552.